Fica Alberto, Julio Verónica, Palma Estefanía, Guinez Dannette, Porte Lorena, Braun Stephanie, Dabanch Jeannette
Servicio de Infectología, Departamento de Medicina, Hospital Militar de Santiago, Santiago, Chile.
Rev Chilena Infectol. 2013 Feb;30(1):65-73. doi: 10.4067/S0716-10182013000100011.
Some aspects of bacteremic cholangitis are unknown in Chile.
To gather more information on clinical, microbiological aspects as well as risk factors for ICU admission, recurrence and antimicrobial resistance.
A retrospective research was performed using medical records of adult patients in a general hospital.
Between 2006-2012, 22 patients with 29 bacteremic events were identified. Previous cholangitis events were reported by 27.3%, 45.5% had recent admissions and, 50% had used antimicrobial compounds. Coledocholithiasis was the most common cause of obstruction (45.5%) followed by cancer (36.4%). One third developed shock (31%), the only factor associated with ICU admission (OR 30, p < 0.05). In 24 of the 29 bacteremic events, the biliary tract was intervened (82.8%) and in 80.8% during the first 72 hours. Gram negative bacilli were predominant (> 80%) and some infrequent agents such as Staphylococcus warneri, Shewanella spp. and, Aeromonas spp. were observed. Among enteric gram negative bacilli, 29.2% presented fluoroquinolone resistance and, 26.1% resistance to third generation cephalosporins, both associated with previous endoscopic retrograde cholangiography (OR 35 and 16.5, respectively p < 0.05). A favorable response was observed in 93.1% of bacte-remic events but in 31.8% of patients cholangitis recurred with or without bacteremia. Recurrence was associated to recent admission (OR 16.5, p = 0.01) and in all cases occurred before 81 days. In-hospital mortality was 9.1% (n = 2), but in only one case associated to sepsis. Average length of stay (LOS) was 17.8 days.
Early intervention of the biliary tract allows a favorable response in patients affected by bacteremic cholangitis, but this condition use intensive care resources, had a prolonged LOS, a recurrent pattern, and is associated with several bacterial species, some of them resistant.
在智利,菌血症性胆管炎的某些方面尚不清楚。
收集更多关于临床、微生物学方面以及重症监护病房(ICU)收治、复发和抗菌药物耐药性的危险因素的信息。
采用一家综合医院成年患者的病历进行回顾性研究。
2006年至2012年期间,共确定了22例患者发生29次菌血症事件。27.3%的患者曾有胆管炎病史,45.5%的患者近期入院,50%的患者曾使用抗菌药物。胆总管结石是最常见的梗阻原因(45.5%),其次是癌症(36.4%)。三分之一的患者发生休克(31%),这是与入住ICU相关的唯一因素(比值比30,p<0.05)。在29次菌血症事件中的24次(82.8%),胆道得到了干预,其中80.8%是在最初72小时内进行的。革兰氏阴性杆菌占主导(>80%),还观察到一些不常见的病原体,如沃氏葡萄球菌、希瓦氏菌属和气单胞菌属。在肠道革兰氏阴性杆菌中,29.2%对氟喹诺酮耐药,26.1%对第三代头孢菌素耐药,两者均与先前的内镜逆行胆管造影有关(比值比分别为35和16.5,p<0.05)。93.1%的菌血症事件观察到良好反应,但31.8%的患者胆管炎复发,有无菌血症均可复发。复发与近期入院有关(比值比16.5,p=0.01),且所有复发病例均发生在81天之前。住院死亡率为9.1%(n=2),但仅1例与脓毒症有关。平均住院时间为17.8天。
胆道的早期干预对菌血症性胆管炎患者有良好反应,但这种疾病需要重症监护资源,住院时间延长,有复发模式,且与多种细菌种类有关,其中一些具有耐药性。